全文获取类型
收费全文 | 271篇 |
免费 | 18篇 |
专业分类
289篇 |
出版年
2023年 | 1篇 |
2022年 | 10篇 |
2021年 | 15篇 |
2020年 | 13篇 |
2019年 | 35篇 |
2018年 | 20篇 |
2017年 | 8篇 |
2016年 | 17篇 |
2015年 | 19篇 |
2014年 | 18篇 |
2013年 | 22篇 |
2012年 | 29篇 |
2011年 | 14篇 |
2010年 | 4篇 |
2009年 | 3篇 |
2008年 | 11篇 |
2007年 | 3篇 |
2006年 | 8篇 |
2005年 | 4篇 |
2004年 | 3篇 |
2003年 | 4篇 |
2001年 | 4篇 |
2000年 | 4篇 |
1999年 | 3篇 |
1998年 | 1篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 3篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1981年 | 1篇 |
排序方式: 共有289条查询结果,搜索用时 15 毫秒
21.
22.
Abdolkarim Moazeni-Roodi Saeid Ghavami Hossein Ansari Mohammad Hashemi 《Journal of cellular biochemistry》2019,120(8):13583-13597
Flap endonuclease 1 (FEN1) has emerged as an important enzyme in the maintenance of genomic instability and preventing carcinogenesis. The relationship between FEN1 −69G>A (rs174538)+4150G>T (rs4246215) polymorphisms and cancer susceptibility has been reported; however, results were inconclusive. In the present study, a meta-analysis of data from eligible reports was carried out to summarize the possible relationship between FEN1 polymorphisms and cancer risk. A total of 11 articles, including 20 studies with 7366 cases and 9028 controls and 18 studies with 6649 cases and 8325 controls for FEN1 rs174538 and FEN1 rs4246215 polymorphisms, respectively, were recruited for meta-analysis. Overall, meta-analyses showed that FEN1 rs174538 and rs4246215 polymorphisms are significantly associated with the decreased risk of cancer. The stratified analysis proposed that both variants were associated with protection against gastrointestinal cancer, breast cancer, hepatocellular cancer, esophageal cancer, gastric cancer, colorectal cancer, and lung cancer. In conclusion, this meta-analysis revealed an association between FEN1 polymorphisms and cancer risk. Additional studies in a larger study population that include subjects from a variety of ethnicities are warranted to further verify our findings. 相似文献
23.
Nasser Hashemi Goradel Siamak Heidarzadeh Samira Jahangiri Bagher Farhood Keywan Mortezaee Neda Khanlarkhani Babak Negahdari 《Journal of cellular physiology》2019,234(3):2337-2344
Colorectal cancer (CRC) is the third most prevalent cancer in the world. There are many risk factors involved in CRC. According to recent findings, the tumor microenvironment and feces samples of patients with CRC are enriched by Fusobacterium nucleatum. Thus, F. nucleatum is proposed as one of the risk factors in the initiation and progression of CRC. The most important mechanisms of Fusobacterium nucleatum involved in CRC carcinogenesis are immune modulation (such as increasing myeloid-derived suppressor cells and inhibitory receptors of natural killer cells), virulence factors (such as FadA and Fap2), microRNAs (such as miR-21), and bacteria metabolism. The aim of this review was to evaluate the mechanisms underlying the action of F. nucleatum in CRC. 相似文献
24.
Samaneh Shojaei Seyed Mahmoud Hashemi Hossein Ghanbarian Mohammad Salehi Samira Mohammadi-Yeganeh 《Journal of cellular physiology》2019,234(4):3394-3409
Mesenchymal stem cells (MSCs) are multipotent cells with the potential to differentiate into different cell types. Owing to their immunosuppressive and anti-inflammatory properties, they are widely used in regenerative medicine, but they have a dual effect on cancer progression and exert both growth-stimulatory or -inhibitory effects on different cancer types. It has been proposed that these controversial effects of MSC in tumor microenvironment (TME) are mediated by their polarization to proinflammatory or anti-inflammatory phenotype. In addition, they can polarize the immune system cells that in turn influence tumor progression. One of the mechanisms involved in the TME communications is extracellular vesicles (EVs). MSCs, as one of cell populations in TME, produce a large amount of EVs that can influence tumor development. Similar to MSC, MSC-EVs can exert both anti- or protumorigenic effects. In the current study, we will investigate the current knowledge related to MSC role in cancer progression with a focus on the MSC-EV content in limiting tumor growth, angiogenesis, and metastasis. We suppose MSC-EVs can be used as safe vehicles for delivering antitumor agents to TME. 相似文献
25.
Esmat?Hashemi Ahmad?Kaviani Masoume?Najafi Mandana?Ebrahimi Homeira?Hooshmand Ali?MontazeriEmail author 《World journal of surgical oncology》2004,2(1):44
Background
Seroma formation is the most frequent postoperative complication after breast cancer surgery. We carried out a study to investigate the effect of various demographic, clinical and therapeutic variables on seroma formation. 相似文献26.
27.
28.
29.
The Mouse GalR2 Galanin Receptor: Genomic Organization, cDNA Cloning, and Functional Characterization 总被引:1,自引:1,他引:1
Ling Pang Tanaz Hashemi Hu-Jung J. Lee Maureen Maguire Michael P. Graziano Marvin Bayne Brian Hawes Gwendolyn Wong Suke Wang 《Journal of neurochemistry》1998,71(6):2252-2259
Abstract: The diverse physiological actions of galanin are thought to be mediated through activation of galanin receptors (GalRs). We report the genomic and cDNA cloning of a mouse GalR that possesses a genomic structure distinct from that of GalR1 and encodes a functional galanin receptor. The mouse GalR gene consists of two exons separated by a single intron within the protein-coding region. The splicing site for the intron is located at the junction between the third transmembrane domain and the second intracellular loop. The cDNA encodes a 370-amino acid putative G protein-coupled receptor that is markedly different from human GalR1 and rat GalR3 (38 and 57%) but shares high homology with rat GalR2 (94%). In binding studies utilizing membranes from COS-7 cells transfected with mouse GalR2 cDNA, the receptor displayed high affinity ( K D = 0.47 n M ) and saturable binding with 125 I-galanin ( B max = 670 fmol/mg). The radioligand binding can be displaced by galanin and its analogues in a rank order: galanin ⋍ M40 ⋍ M15 ⋍ M35 ⋍ C7 ⋍ galanin (2–29) ⋍ galanin (1–16) ≫ galanin (10–29) ⋍ galanin (3–29), which resembles the pharmacological profile of the rat GalR2. Receptor activation by galanin in COS-7 cells stimulated phosphoinositide metabolism, which was not reversed by pertussis toxin. Thus, the galanin receptor encoded in the cloned mouse GalR gene is the type 2 galanin receptor and is active in both ligand binding and signaling assays. 相似文献
30.
BioMetals - Small molecules have potential usage in cancer therapy due to their remarkable potency of disarranging the natural structure of nucleic acids. In this study, two complexes... 相似文献